clinical trial · NCT05192382
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
AcromegalyPaltusotinePlacebo
brief summary
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.
started
Dec 17, 2021
primary completion
Jan 20, 2024
completion
Jan 1, 2028
last updated
Apr 23, 2026
official title
A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Non-pharmacologically Treated Acromegaly (PATHFNDR-2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol